Prolonged survival in malignant pheochromocytoma of the organ of zuckerkandl with pharmacological treatment

Scharf, Y.; Am, Nahir; Os, Better; Koten, A; Yb, Arieh; Gellei, B

doi:10.1002/1097-0142(197303)31:3<746::aid-cncr2820310339>3.0.co;2-1

Cited by 23 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The behavior of malignant pheochromocytomas is highly variable but the average survival period after detection of metastases was given as only 3 years in a study reported in 1961 [27]. More recent reports indicate a longer survival [11, [24][25][26]281 as is the case with our patients. Death from recurrent and malignant pheochromocytomas frequently arises from some cardiovascular or cerebrovascular event due to high circulating catecholamine, rather than from tumor growth.…”

Section: Discussionsupporting

confidence: 61%

Late recurrence of benign pheochromocytomas: The necessity for long term follow‐up

Sparagana

1988

Journal of Surgical Oncology

View full text Add to dashboard Cite

Two patients who had removal of seemingly benign pheochromocytomas had recurrences 10 and 14 years later despite normal catecholamine excretion for 7 and 9 years postoperatively. The first patient returned with a myocardial infarction and an apparently solitary recurrence; the second patient with a stroke and metastatic disease. Both patients had recurrence of hypertension and increased catecholamine excretion. They were given phenoxybenzamine and are doing satisfactorily 7 and 9 years after their recurrences. Such patients should be followed after surgery for 15 or more years for early detection of recurrences. Prompt therapy should reduce the risk of undesirable complications.

show abstract

Section: Discussionsupporting

confidence: 61%

Late recurrence of benign pheochromocytomas: The necessity for long term follow‐up

Sparagana

1988

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Nevertheless, evidence began to accumulate, paving the potential use (reposition) of propranolol as an antitumor drug. This use is supported by several case reports [ 9 , 10 , 11 , 12 ] that postulated the use of propranolol in a rare tumor-like pheochromocytoma to reduce hypertension generated by catecholamines’ secretion. Interestingly, these studies outlined (but did not relate) the absence of metastases and tumor growth amelioration without noticeable side effects, together with the normalization of the heart rate and blood pressure.…”

Section: Why Propranolol?mentioning

confidence: 64%

Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

Albiñana

Gallardo-Vara

Casado‐Vela

et al. 2022

JCM

View full text Add to dashboard Cite

Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies.

show abstract

“…The effect of various treatments including chemotherapy on bone metastasis has not been completely satisfactory (21)(22)(23)(24).…”

Section: Discussionmentioning

confidence: 99%

Cardiac Malignant Pheochromocytoma with Bone Metastases.

Arai

Naruse

et al. 1998

Intern. Med.

View full text Add to dashboard Cite

A patient with malignant cardiac pheochromocytomawith bone metastases is described. The primary tumor was located between the pulmonary trunk and the left atrium, while metastatic lesions were found in the iliac bones. Treatments with antihypertensive agents, a-methylparatyrosine, and combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine partially improved the patient's symptoms, catecholamine levels, and the metastatic lesion of the iliac bones. However, the primary tumor in the heart progressively increased in size and the patient died of disseminated intravascular coagulation and other various complications about 4 years after the diagnosis of the disease. (Internal Medicine 37: 940-944, 1998)

show abstract

Prolonged survival in malignant pheochromocytoma of the organ of zuckerkandl with pharmacological treatment

Cited by 23 publications

References 16 publications

Late recurrence of benign pheochromocytomas: The necessity for long term follow‐up

Late recurrence of benign pheochromocytomas: The necessity for long term follow‐up

Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

Cardiac Malignant Pheochromocytoma with Bone Metastases.

Contact Info

Product

Resources

About